ALX ONCOLOGY HOLDINGS INC — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 28/100
What the filing says
ALX Oncology (market cap ~$18M) reported Q3 2026 net loss of $21.8M ($0.15/share) on essentially flat R&D spend of $17.5M vs. $17.4M YoY. Cash position strengthened to $147.2M (from $48.3M at year-end 2025), sufficient to fund operations through H1 2028. Key catalysts: ALX2004 Phase 1 safety/efficacy data expected December 2026 (35 patients enrolled); ASPEN-09-Breast Phase 2 topline from ~120 patients expected H2 2027. No counterparties, partnerships, or financing transactions disclosed.
Why this rating
Routine quarterly disclosure; cash raise extended runway substantially. Clinical timeline advancement is positive but no concrete data yet. Small relative to market cap.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.